In the highly regulated pharmaceutical industry, where clinical development is largely outsourced, procurement teams play a critical role in enabling successful medical trials. While clinical studies designed to test the safety and efficacy of new drugs are essential, their success can never be guaranteed.
In fact, it is widely accepted that the majority of clinical trials will fail. While scientific uncertainty is unavoidable, the risk of failure caused by operational execution can be significantly reduced. Trials are far more likely to succeed when pharmaceutical procurement teams secure high-quality, mission-critical services and manage supplier relationships effectively. When procurement is equipped to do this well, it delivers meaningful value to the wider business.
Chief Procurement Officers, or CPOs, therefore sit at a pivotal point. Their teams must balance multiple priorities. On one side, they need to secure specialist expertise capable of delivering complex work within tight timelines while protecting data integrity. On the other, they must ensure that every outsourced activity complies with an exceptionally demanding regulatory environment.
Procurement teams that strike this balance effectively can play a decisive role in getting medical trials over the line.
So how can CPOs enable their teams to secure the right expertise, deliver on time, and remain compliant within an outsourced model? Ultimately, success depends on how procurement engages with suppliers across the pharmaceutical supply chain.
What are pharma CPOs juggling?
Before exploring how supplier engagement enables successful trials, it is important to understand the scale of the challenge facing procurement leaders. Clinical trials are both expensive and high-risk. Only a small proportion of drugs that enter trials ever reach the market. While estimates vary, the general consensus across the industry is that only around 10 to 20 percent of clinical trial drugs ultimately receive approval. Even within this range, outcomes often sit closer to the lower end. Costs compound this risk. A relatively small Phase III trial can exceed £100 million in expenditure. With such significant investment at stake, even marginal improvements in execution can have a meaningful impact on return on investment.
Procurement’s ability to influence outcomes lies in its capacity to secure timely, high-quality operational expertise that delivers robust studies within the regulatory framework. This is where procurement in pharmaceutical moves beyond commercial negotiation and into value creation.
The regulatory environment affects nearly every aspect of development activity. Supplier selection is a key risk area. Poor oversight or misalignment can expose businesses to regulatory fines and serious reputational damage. Procurement must also ensure that outsourced activities across departments remain compliant and that suppliers understand and meet regulatory expectations.
Complicating matters further, regulations evolve continually. New requirements regularly come into force, creating a moving compliance target. Procurement teams must remain informed and help the wider organisation understand how regulatory change affects outsourced development models and supplier responsibilities.
Most pharmaceutical companies now rely heavily on external providers to deliver clinical trials. What was once an in-house activity has become almost entirely outsourced, supported by a global ecosystem of specialist service providers. These suppliers bring deep expertise and operational capability, but their external position means procurement must work harder to keep activities aligned with internal objectives. Against this backdrop, effective collaboration with suppliers becomes essential.
How can teams really collaborate with external experts?
Successful clinical trials depend on strong collaboration across the pharmaceutical supply chain. Procurement teams are uniquely positioned to enable this collaboration by acting as a bridge between internal stakeholders and external experts.
A central requirement of any trial is the Trial Master File. This repository must remain complete and up to date at all times, containing all documentation that regulators may request. This includes supplier performance data, oversight metrics, and operational records. Maintaining this standard demands a constant flow of accurate data from suppliers and study physicians.
Given the volume of information involved and the complexity of trial execution, procurement must work closely with suppliers to ensure data quality, timeliness, and regulatory compliance. By treating suppliers as an extension of the internal team rather than a separate entity, procurement can significantly improve outcomes.
One practical mechanism to support collaboration and shared accountability is the use of performance-linked commercial structures. A penalty or earn-back bonus approach can help align incentives. In this model, a portion of supplier fees is held back and released only when agreed performance and quality criteria are met. Additional bonuses can reward suppliers for exceeding expectations or achieving stretch goals. These approaches encourage shared ownership of outcomes while reinforcing the importance of quality, compliance, and delivery discipline.
Why is trust so crucial?
Beyond governance and incentives, trust plays a vital role in effective supplier collaboration. Many pharmaceutical suppliers employ hundreds of highly qualified professionals, including PhDs, clinicians, statisticians, and operational specialists. In many cases, their experience in specific indications or trial designs may exceed that of the sponsoring organisation.
This intellectual capital represents a valuable resource that procurement leaders should actively access. For example, when running a study in a rare or unusual disease area, suppliers may have far greater exposure and insight than the sponsor. Their experience can inform not only trial execution but also the operational strategy that underpins study success.
Trusting suppliers in practice may involve allowing them to apply their own Standard Operating Procedures or contributing input to study protocols. Some sponsors insist on imposing internal procedures across all activities, even when supplier processes are equally robust. This can limit efficiency and undermine supplier expertise.
A useful analogy is that of a restaurant. Ordering a dish while dictating exactly how it must be prepared rarely delivers the best result. In the same way, allowing expert suppliers to lead where appropriate can improve trial outcomes. Trust does not remove sponsor accountability. Rather, it recognises that collaboration and respect for expertise are essential ingredients for success.
Getting trials over the line through supplier partnership
For pharmaceutical CPOs, supplier collaboration is no longer optional. It is a strategic necessity. By enabling procurement teams to work closely with suppliers, share risk, and access external expertise, organisations can improve compliance, protect data integrity, and increase the likelihood of clinical success. When procurement teams operate as true partners within the pharmaceutical industry, they help their businesses deliver high-quality trials, bring critical drugs to market, and ultimately improve patient outcomes.